ASCO Ovarian Cancer Spotlight | Conferences

Comprehensive Genomic Profiling Helps Detect Patients With Ovarian Cancer Likely to Benefit from PARP Inhibition

June 06, 2017

Approximately 25% of patients with BRCA wild-type serous ovarian cancer may benefit from treatment with PARP inhibitors, along with 12.7% of patients with a non-serous histology, according to findings of genomic analyses in patients with ovarian cancer presented during the 2017 ASCO Annual Meeting that demonstrate that comprehensive genomic profiling is a valuable tool to integrate into routine ovarian cancer treatment decision making and clinical trial design.

An Overview of a Study Exploring Mirvetuximab Soravtansine in Ovarian Cancer

June 05, 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.

Olaparib/Cediranib Combination Leads to Continued PFS Improvement in Ovarian Cancer

June 04, 2017

Progression-free survival (PFS) continues to be superior with the combination of cediranib maleate and olaparib (Lynparza) compared with olaparib alone in patients with recurrent platinum-sensitive ovarian cancer in a randomized open-label study with follow-up to December 2016.

No QoL Decrement With Olaparib for Recurrent Ovarian Cancer

June 04, 2017

Patients with recurrent, platinum-sensitive ovarian cancer and germline BRCA mutations had significant improvement in progression-free survival (PFS) with no decrement in health-related quality of life (hr-QoL) during maintenance therapy with olaparib (Lynparza), according to a review of patient-reported outcomes in a randomized trial.

Olaparib Shows Promise as Long-term Maintenance Therapy in Relapsed Serous Ovarian Cancer in Final Study 19 Analysis

June 04, 2017

The PARP inhibitor olaparib (Lynparza) provides clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer, according to the protocol-specified final overall survival (OS) analysis of the phase II Study 19 trial presented during the 2017 ASCO Annual Meeting.

Results for Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer

June 04, 2017

Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer.

Second Surgery Extends Progression-Free Survival in Recurrent Ovarian Cancer With Positive AGO Score

June 04, 2017

A second cytoreductive surgery followed by platinum-based chemotherapy extended progression-free survival (PFS) compared with platinum-based chemotherapy alone in patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score.